1887

Abstract

The gut microbiota exerts a significant influence on human health and disease. While compositional changes in the gut microbiota in specific diseases can easily be determined, we lack a detailed mechanistic understanding of how these changes exert effects at the cellular level. However, the putative local and systemic effects on human physiology that are attributed to the gut microbiota are clearly being mediated through molecular communication. Here, we determined the effects of gut microbiome-derived metabolites -tryptophan, butyrate, trimethylamine (TMA), 3-methyl-4-(trimethylammonio)butanoate (3,4-TMAB), 4-(trimethylammonio)pentanoate (4-TMAP), ursodeoxycholic acid (UDCA), glycocholic acid (GCA) and benzoate on the first line of defence in the gut. Using models of intestinal barrier integrity and studying the interaction of macrophages with pathogenic and non-pathogenic bacteria, we could ascertain the influence of these metabolites at the cellular level at physiologically relevant concentrations. Nearly all metabolites exerted positive effects on barrier function, but butyrate prevented a reduction in transepithelial resistance in the presence of the pathogen , despite inducing increased apoptosis and exerting increased cytotoxicity. Induction of IL-8 was unaffected by all metabolites, but GCA stimulated increased intra-macrophage growth of and tumour necrosis-alpha (TNF-α) release. Butyrate, 3,4-TMAB and benzoate all increased TNF-α release independent of bacterial replication. These findings reiterate the complexity of understanding microbiome effects on host physiology and underline that microbiome metabolites are crucial mediators of barrier function and the innate response to infection. Understanding these metabolites at the cellular level will allow us to move towards a better mechanistic understanding of microbiome influence over host physiology, a crucial step in advancing microbiome research.

Funding
This study was supported by the:
  • Biotechnology and Biological Sciences Research Council (Award BB/V001876/1)
    • Principle Award Recipient: DanielM Wall
  • Biotechnology and Biological Sciences Research Council (Award BB/V001876/1)
    • Principle Award Recipient: RichardGoodwin
  • Biotechnology and Biological Sciences Research Council (Award BB/V001876/1)
    • Principle Award Recipient: RichardBurchmore
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.001504
2024-10-11
2024-11-09
Loading full text...

Full text loading...

/deliver/fulltext/micro/170/10/mic001504.html?itemId=/content/journal/micro/10.1099/mic.0.001504&mimeType=html&fmt=ahah

References

  1. Clemente JC, Manasson J, Scher JU. The role of the gut microbiome in systemic inflammatory disease. BMJ 2018; 360:j5145 [View Article] [PubMed]
    [Google Scholar]
  2. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol 2015; 31:69–75 [View Article] [PubMed]
    [Google Scholar]
  3. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A 2012; 109:594–599 [View Article] [PubMed]
    [Google Scholar]
  4. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108:1566–1581 [View Article] [PubMed]
    [Google Scholar]
  5. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008; 8:411–420 [View Article]
    [Google Scholar]
  6. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke J-D et al. Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14:189 [View Article] [PubMed]
    [Google Scholar]
  7. Michielan A, D’Incà R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm 2015; 2015:628157 [View Article] [PubMed]
    [Google Scholar]
  8. Berkes J, Viswanathan VK, Savkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003; 52:439–451 [View Article] [PubMed]
    [Google Scholar]
  9. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291:881–884 [View Article] [PubMed]
    [Google Scholar]
  10. Zareie M, Riff J, Donato K, McKay DM, Perdue MH et al. Novel effects of the prototype translocating Escherichia coli, strain C25 on intestinal epithelial structure and barrier function. Cell Microbiol 2005; 7:1782–1797 [View Article] [PubMed]
    [Google Scholar]
  11. Khaloian S, Rath E, Hammoudi N, Gleisinger E, Blutke A et al. Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn’s disease recurrence. Gut 2020; 69:1939–1951 [View Article] [PubMed]
    [Google Scholar]
  12. Goethel A, Croitoru K, Philpott DJ. The interplay between microbes and the immune response in inflammatory bowel disease. J Physiol 2018; 596:3869–3882 [View Article]
    [Google Scholar]
  13. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637–650 [View Article] [PubMed]
    [Google Scholar]
  14. Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis 2014; 20:166–175 [View Article] [PubMed]
    [Google Scholar]
  15. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014; 13:3–10 [View Article] [PubMed]
    [Google Scholar]
  16. Hisamatsu T, Kanai T, Mikami Y, Yoneno K, Matsuoka K et al. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther 2013; 137:283–297 [View Article] [PubMed]
    [Google Scholar]
  17. Korta A, Kula J, Gomułka K. The role of IL-23 in the pathogenesis and therapy of inflammatory bowel disease. Int J Mol Sci 2023; 24:10172 [View Article] [PubMed]
    [Google Scholar]
  18. Zhang S, Morgan X, Dogan B, Martin F-P, Strickler S et al. Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn’s disease. JCI Insight 2022; 7:e157013 [View Article] [PubMed]
    [Google Scholar]
  19. Escribano-Vazquez U, Verstraeten S, Martin R, Chain F, Langella P et al. The commensal Escherichia coli CEC15 reinforces intestinal defences in gnotobiotic mice and is protective in a chronic colitis mouse model. Sci Rep 2019; 9:11431 [View Article] [PubMed]
    [Google Scholar]
  20. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 2009; 106:3698–3703 [View Article] [PubMed]
    [Google Scholar]
  21. Aldars-García L, Gisbert JP, Chaparro M. Metabolomics insights into inflammatory bowel disease: a comprehensive review. Pharmaceuticals 2021; 14:1190 [View Article] [PubMed]
    [Google Scholar]
  22. Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R et al. Short Chain Fatty Acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 2019; 10:277 [View Article] [PubMed]
    [Google Scholar]
  23. Gupta NK, Thaker AI, Kanuri N, Riehl TE, Rowley CW et al. Serum analysis of tryptophan catabolism pathway: correlation with Crohn’s disease activity. Inflamm Bowel Dis 2012; 18:1214–1220 [View Article] [PubMed]
    [Google Scholar]
  24. Gnewuch C, Liebisch G, Langmann T, Dieplinger B, Mueller T et al. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol 2009; 15:3134–3141 [View Article] [PubMed]
    [Google Scholar]
  25. Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007; 6:546–551 [View Article]
    [Google Scholar]
  26. Casselbrant A, Fändriks L, Wallenius V. Glycocholic acid and butyrate synergistically increase vitamin D-induced calcium uptake in Caco-2 intestinal epithelial cell monolayers. Bone Rep 2020; 13:100294 [View Article] [PubMed]
    [Google Scholar]
  27. Hulme H, Meikle LM, Strittmatter N, van der Hooft JJJ, Swales J et al. Microbiome-derived carnitine mimics as previously unknown mediators of gut-brain axis communication. Sci Adv 2020; 6:eaax6328 [View Article] [PubMed]
    [Google Scholar]
  28. Wu W-K, Chen C-C, Liu P-Y, Panyod S, Liao B-Y et al. Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut 2019; 68:1439–1449 [View Article] [PubMed]
    [Google Scholar]
  29. Keely SJ, Steer CJ, Lajczak-McGinley NK. Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases?. Am J Physiol Gastrointest Liver Physiol 2019; 317:G872–G881 [View Article] [PubMed]
    [Google Scholar]
  30. Gerasimidis K, Bryden K, Chen X, Papachristou E, Verney A et al. The impact of food additives, artificial sweeteners and domestic hygiene products on the human gut microbiome and its fibre fermentation capacity. Eur J Nutr 2020; 59:3213–3230 [View Article] [PubMed]
    [Google Scholar]
  31. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013; 4:280 [View Article] [PubMed]
    [Google Scholar]
  32. Stolfi C, Maresca C, Monteleone G, Laudisi F. Implication of intestinal barrier dysfunction in gut dysbiosis and diseases. Biomedicines 2022; 10:289 [View Article] [PubMed]
    [Google Scholar]
  33. Wine E, Ossa JC, Gray-Owen SD, Sherman PM. Adherent-invasive Escherichia coli target the epithelial barrier. Gut Microbes 2010; 1:80–84 [View Article] [PubMed]
    [Google Scholar]
  34. Calzadilla N, Comiskey SM, Dudeja PK, Saksena S, Gill RK et al. Bile acids as inflammatory mediators and modulators of intestinal permeability. Front Immunol 2022; 13:1021924 [View Article] [PubMed]
    [Google Scholar]
  35. Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 2007; 61:37–41 [View Article] [PubMed]
    [Google Scholar]
  36. Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 2020; 117:19376–19387 [View Article]
    [Google Scholar]
  37. Jaworska K, Konop M, Bielinska K, Hutsch T, Dziekiewicz M et al. Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: a new, non-invasive marker of a functional intestinal lesion. Exp Physiol 2019; 104:1226–1236 [View Article] [PubMed]
    [Google Scholar]
  38. Walczak-Nowicka ŁJ, Herbet M. Sodium benzoate-harmfulness and potential use in therapies for disorders related to the nervous system: a review. Nutrients 2022; 14:1497 [View Article] [PubMed]
    [Google Scholar]
  39. Campbell HE, Escudier MP, Patel P, Challacombe SJ, Sanderson JD et al. Review article: cinnamon- and benzoate-free diet as a primary treatment for orofacial granulomatosis. Aliment Pharmacol Therapeut 2011; 34:687–701 [View Article]
    [Google Scholar]
  40. Shi X, Li X, Li X, He Z, Chen X et al. Antibacterial properties of TMA against Escherichia coli and effect of temperature and storage duration on TMA content, lysozyme activity and content in eggs. Foods 2022; 11:527 [View Article]
    [Google Scholar]
  41. Chen H, Zhong Q. Antibacterial activity of acidified sodium benzoate against Escherichia coli O157:H7, Salmonella enterica, and Listeria monocytogenes in tryptic soy broth and on cherry tomatoes. Int J Food Microbiol 2018; 274:38–44 [View Article] [PubMed]
    [Google Scholar]
  42. Lin MH, Khnykin D. Fatty acid transporters in skin development, function and disease. Biochim Biophys Acta 2014; 1841:362–368 [View Article] [PubMed]
    [Google Scholar]
  43. Deng J, Zhao F, Yu X, Zhao Y, Li D et al. Expression of aquaporin 4 and breakdown of the blood-brain barrier after hypoglycemia-induced brain edema in rats. PLoS One 2014; 9:e107022 [View Article]
    [Google Scholar]
  44. Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML et al. TEER measurement techniques for in vitro barrier model systems. J Lab Autom 2015; 20:107–126 [View Article] [PubMed]
    [Google Scholar]
  45. Chen J, Vitetta L. The role of butyrate in attenuating pathobiont-induced hyperinflammation. Immune Netw 2020; 20:e15 [View Article] [PubMed]
    [Google Scholar]
  46. Zheng L, Kelly CJ, Battista KD, Schaefer R, Lanis JM et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J Immunol 2017; 199:2976–2984 [View Article] [PubMed]
    [Google Scholar]
  47. Nunes T, Bernardazzi C, de Souza HS. Cell death and inflammatory bowel diseases: apoptosis, necrosis, and autophagy in the intestinal epithelium. Biomed Res Int 2014; 2014:218493 [View Article] [PubMed]
    [Google Scholar]
  48. Ruemmele FM, Schwartz S, Seidman EG, Dionne S, Levy E et al. Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut 2003; 52:94–100 [View Article] [PubMed]
    [Google Scholar]
  49. Pant K, Yadav AK, Gupta P, Islam R, Saraya A et al. Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells. Redox Biol 2017; 12:340–349 [View Article] [PubMed]
    [Google Scholar]
  50. Zamaraeva MV, Sabirov RZ, Maeno E, Ando-Akatsuka Y, Bessonova SV et al. Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase. Cell Death Differ 2005; 12:1390–1397 [View Article]
    [Google Scholar]
  51. Guerbette T, Boudry G, Lan A. Mitochondrial function in intestinal epithelium homeostasis and modulation in diet-induced obesity. Mol Metab 2022; 63:101546 [View Article] [PubMed]
    [Google Scholar]
  52. Mottawea W, Chiang C-K, Mühlbauer M, Starr AE, Butcher J et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease. Nat Commun 2016; 7:13419 [View Article] [PubMed]
    [Google Scholar]
  53. Jackson DN, Panopoulos M, Neumann WL, Turner K, Cantarel BL et al. Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis. Gut 2020; 69:1928–1938 [View Article] [PubMed]
    [Google Scholar]
  54. Nicholls DG. Mitochondrial membrane potential and aging. Aging Cell 2004; 3:35–40 [View Article] [PubMed]
    [Google Scholar]
  55. Li Y, Yang S, Jin X, Li D, Lu J et al. Mitochondria as novel mediators linking gut microbiota to atherosclerosis that is ameliorated by herbal medicine: a review. Front Pharmacol 2023; 14:52 [View Article]
    [Google Scholar]
  56. Tars K, Leitans J, Kazaks A, Zelencova D, Liepinsh E et al. Targeting carnitine biosynthesis: discovery of new inhibitors against γ-butyrobetaine hydroxylase. J Med Chem 2014; 57:2213–2236 [View Article] [PubMed]
    [Google Scholar]
  57. Nguyen D, Samson SL, Reddy VT, Gonzalez EV, Sekhar RV. Impaired mitochondrial fatty acid oxidation and insulin resistance in aging: novel protective role of glutathione. Aging Cell 2013; 12:415–425 [View Article] [PubMed]
    [Google Scholar]
  58. Mikó E, Vida A, Kovács T, Ujlaki G, Trencsényi G et al. Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness. Biochimica et Biophysica Acta (BBA) - Bioenergetics 2018; 1859:958–974 [View Article]
    [Google Scholar]
  59. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap--bile acids in metabolic control. Nat Rev Endocrinol 2014; 10:488–498 [View Article] [PubMed]
    [Google Scholar]
  60. Xu W, Li T, Gao L, Lenahan C, Zheng J et al. Sodium benzoate attenuates secondary brain injury by inhibiting neuronal apoptosis and reducing mitochondria-mediated oxidative stress in a rat model of intracerebral hemorrhage: possible involvement of DJ-1/Akt/IKK/NFκB pathway. Front Mol Neurosci 2019; 12:105 [View Article]
    [Google Scholar]
  61. Tapia R, Kralicek SE, Hecht GA. Modulation of epithelial cell polarity by bacterial pathogens. Ann N Y Acad Sci 2017; 1405:16–24 [View Article] [PubMed]
    [Google Scholar]
  62. Gwilt KB, Thiagarajah JR. Membrane lipids in epithelial polarity: sorting out the pips. Front Cell Dev Biol 2022; 10:1124
    [Google Scholar]
  63. Stoops EH, Caplan MJ. Trafficking to the apical and basolateral membranes in polarized epithelial cells. J Am Soc Nephrol 2014; 25:1375–1386 [View Article] [PubMed]
    [Google Scholar]
  64. Andrews C, McLean MH, Durum SK. Cytokine tuning of intestinal epithelial function. Front Immunol 2018; 9:1270 [View Article] [PubMed]
    [Google Scholar]
  65. Huang DB, DuPont HL, Jiang Z-D, Carlin L, Okhuysen PC. Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic Escherichia coli. Clin Diagn Lab Immunol 2004; 11:548–551 [View Article] [PubMed]
    [Google Scholar]
  66. Healy LL, Cronin JG, Sheldon IM. Polarized epithelial cells secrete interleukin 6 apically in the bovine endometrium. Biol Reprod 2015; 92:151 [View Article] [PubMed]
    [Google Scholar]
  67. Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev 2019; 32:e00060-18 [View Article] [PubMed]
    [Google Scholar]
  68. Russo TA, Johnson JR. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis 2000; 181:1753–1754 [View Article] [PubMed]
    [Google Scholar]
  69. Hernandes RT, Elias WP, Vieira MAM, Gomes TAT. An overview of atypical enteropathogenic Escherichia coli. FEMS Microbiol Lett 2009; 297:137–149 [View Article] [PubMed]
    [Google Scholar]
  70. Cai Y, Sugimoto C, Arainga M, Alvarez X, Didier ES et al. In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans. J Immunol 2014; 192:2821–2829 [View Article] [PubMed]
    [Google Scholar]
  71. Ebert EC. IL-15 converts human intestinal intraepithelial lymphocytes to CD94 producers of IFN-gamma and IL-10, the latter promoting Fas ligand-mediated cytotoxicity. Immunology 2005; 115:118–126 [View Article] [PubMed]
    [Google Scholar]
  72. Mention J-J, Ben Ahmed M, Bègue B, Barbe U, Verkarre V et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003; 125:730–745 [View Article] [PubMed]
    [Google Scholar]
  73. Mahapatro M, Erkert L, Becker C. Cytokine-mediated crosstalk between immune cells and epithelial cells in the gut. Cells 2021; 10:111 [View Article] [PubMed]
    [Google Scholar]
  74. Ge X, Huang S, Ren C, Zhao L. Taurocholic acid and glycocholic acid inhibit inflammation and activate farnesoid X receptor expression in LPS-stimulated zebrafish and macrophages. Molecules 2023; 28:2005 [View Article] [PubMed]
    [Google Scholar]
  75. Zhang YL, Li ZJ, Gou HZ, Song XJ, Zhang L. The gut microbiota-bile acid axis: a potential therapeutic target for liver fibrosis. Front Cell Infect Microbiol 2022; 12:945368 [View Article] [PubMed]
    [Google Scholar]
  76. Pi Y, Wu Y, Zhang X, Lu D, Han D et al. Gut microbiota-derived ursodeoxycholic acid alleviates low birth weight-induced colonic inflammation by enhancing M2 macrophage polarization. Microbiome 2023; 11:19 [View Article] [PubMed]
    [Google Scholar]
  77. Delmas J, Gibold L, Faïs T, Batista S, Leremboure M et al. Metabolic adaptation of adherent-invasive Escherichia coli to exposure to bile salts. Sci Rep 2019; 9:2175 [View Article] [PubMed]
    [Google Scholar]
  78. Hamilton JP, Xie G, Raufman J-P, Hogan S, Griffin TL et al. Human cecal bile acids: concentration and spectrum. Am J Physiol Gastrointest Liver Physiol 2007; 293:G256–G263 [View Article] [PubMed]
    [Google Scholar]
  79. Oshima Y, Wakino S, Kanda T, Tajima T, Itoh T et al. Sodium benzoate attenuates 2,8-dihydroxyadenine nephropathy by inhibiting monocyte/macrophage TNF-α expression. Sci Rep 2023; 13: [View Article]
    [Google Scholar]
/content/journal/micro/10.1099/mic.0.001504
Loading
/content/journal/micro/10.1099/mic.0.001504
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error